HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FTC consent agreement

This article was originally published in The Rose Sheet

Executive Summary

Federal Trade Commission gives final approval to a consent agreement with Thomas Fenton, a former officer or director of infomercial product Synchronal Corporation, for his role in promoting the Omexin System for Hair, a purported baldness remedy. Under the consent agreement, Fenton is prohibited from making "false and unsubstantiated" claims for any baldness treatment product, and must have scientific evidence supporting any performance claims for any food, drug or device he promotes in the future. Other provisions of the consent agreement include a prohibition on representing an ad as an independent TV program. FTC announced last June that Synchronal had agreed to pay $3.5 mil. in a proposed settlement ("The Rose Sheet" June 7, 1993, p. 1)
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS000515

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel